BEGIN:VCALENDAR VERSION:2.0 PRODID:-//KESHO - ECPv6.17.5//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:KESHO X-ORIGINAL-URL:https://kesho-kenya.org X-WR-CALDESC:Events for KESHO REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:Africa/Nairobi BEGIN:STANDARD TZOFFSETFROM:+0300 TZOFFSETTO:+0300 TZNAME:EAT DTSTART:20180101T000000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20200827T070000 DTEND;TZID=Africa/Nairobi:20200827T203000 DTSTAMP:20211024T154948Z CREATED:20210604T162505Z LAST-MODIFIED:20211024T154948Z UID:5294-1598511600-1598560200@kesho-kenya.org SUMMARY:Cancer and Thrombosis Current Perspective DESCRIPTION:[vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/cancer-and-thrombosis-current-perspective/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/06/image_2021-06-04_193129.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20200811T191500 DTEND;TZID=Africa/Nairobi:20200811T201500 DTSTAMP:20250622T142511Z CREATED:20210813T143324Z LAST-MODIFIED:20250622T142511Z UID:5898-1597173300-1597176900@kesho-kenya.org SUMMARY:Emerging Therapies in Hodgkin's Lymphoma Management - Treatment Beyond The Basics DESCRIPTION:[vc_row][vc_column][vc_column_text] \nModerator: Dr. Miriam Mutebi \nSponsor: Takeda\, a pharmaceutical company with a patient assistance program for Hodgkin’s lymphoma in Kenya. \nPresenters: \n\nDr. Anna Sureda\, Head of the Clinical Hematology Department and the Stem Cell Transplantation program of Institut Catala d’Oncologia – Hospitalet\, Barcelona\n\nHodgkin’s lymphoma (HL) is one of the most curable hematological malignancies with first-line treatment\, which is a combination of radiotherapy and chemotherapy. Autologous hematopoietic stem cell transplantation (auto-HCT) is the standard therapy for HL patients relapsing after first-line chemotherapy. The use of allogeneic stem cell transplantation (ASCT) has improved the overall survival (OS) of patients over time.  To improve the landscape of chemotherapy treatment for refractory disease\, a new drug\, Brentuximab vedotin\, has been introduced. This drug is an antibody-drug conjugate (ADC) consisting of 3 components; it binds to CD30 forming a complex that is internalized and traffics to the lysosome. The drug was granted accelerated approval by the US FDA in 2011.  The European Medicines Agency (EMA) approved this drug in 2012 for the treatment of adult patients with relapsed or refractory CD30+ HL\, anaplastic large cell lymphoma\, and those at increased risk of relapse or progression following ASCT. The efficacy reported as median observation time from the first dose at study closure was 35.1 months (1.8-72.9). Studies revealed that Brentuximab vedotin and ESHAP are highly effective as second-line therapy for Hodgkin’s patients. Brentuximab vedotin was the first targeted therapy that was tested in patients with relapsed/refractory HL. It was very effective as a single drug in patients that relapse or progress after auto-HCT. Brentuximab vedotin is able to potentially increase the number of patients that are candidates to auto-HCT. It improves progression-free survival (PFS) in those patients with a high risk of relapse after auto-HCT when used as a consolidation strategy. It has demonstrated an adequate and safe toxicity profile\, even in HIV-positive patients with HL. Brentuximab vedotin is being used in other settings with very interesting results (RR setting in combination with chemotherapy\, first line). However\, the cost of the treatment in Kenya is quite high; a single vial costs Kshs. 330\,000. A patient assistance program in partnership with Takeda is helping patients in Kenya who cannot afford to pay\, to complete their treatment. Although this program is run in private hospitals\, physicians seeing patients at public facilities can refer the patients to the private facilities for assistance\, but continue to follow up on the patients. \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/emerging-therapies-in-hodgkins-lymphoma-management-treatment-beyond-the-basics/ CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_170809.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20200730T191500 DTEND;TZID=Africa/Nairobi:20200730T203000 DTSTAMP:20250622T142511Z CREATED:20210810T101728Z LAST-MODIFIED:20250622T142511Z UID:5839-1596136500-1596141000@kesho-kenya.org SUMMARY:Ovarian Cancer\, The Good\, The Bad\, And The Ugly DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Andrew Odhiambo\, Consultant Medical Oncologist & Lecturer\, University of Nairobi \nSponsor: Merck \nPresenters: \n\nDr. Benjamin Odongo Elly\, Gynecologic Oncologist at Moi Teaching and Referral University.\n\nMoi Teaching and Referral Hospital (MTRH) cancer center offers a holistic approach to cancer treatment. Germ cell tumors account for 10-115% of all ovarian tumors and affect young females of reproductive age. They are very chemosensitive hence are curable\, using fertility-sparing surgery. Stromal tumors account for 3-5% of all ovarian tumors and affect women of all ages. These tumors are diagnosed early and are histologically low-grade\, with a good prognosis\, when treated with surgery\,  followed by adjuvant treatment. However\, some tumors are aggressive and lethal. Epithelial tumors represent 80-85% of all ovarian tumors. They have a poor prognosis and are always detected late. Warning signs include abdominal bloating\, abdominal/pelvic pain\, bowel/bladder symptoms\, and irregular vaginal bleeding. Prevention of ovarian cancer is by avoidance of risk factors and prophylactic surgery in high-risk women. There is currently no good screening test for the general population. Diagnosis is by appropriate physical examination\, pelvic/transvaginal ultrasound\, tumor markers\, and CT scan. The majority of patients are diagnosed with advanced-stage disease (stage III or IV) leading to poor overall 5-year survival. However\, patients are living longer with the disease due to advances in surgery and chemotherapy treatment. As a country\, there is a need to improve the early diagnosis of ovarian cancer through advocacy\, patient education\, human resource\, training capacity building\, and availing resources to the health care facilities.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/ovarian-cancer-the-good-the-bad-and-the-ugly/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2020,Webinar Recording Available END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20191121T200000 DTEND;TZID=Africa/Nairobi:20191121T220000 DTSTAMP:20250622T142511Z CREATED:20210420T152935Z LAST-MODIFIED:20250622T142511Z UID:4731-1574366400-1574373600@kesho-kenya.org SUMMARY:TOPIC: Management of Brain Tumors DESCRIPTION:[vc_row][vc_column][vc_column_text] \nFinally\, KESHO partnered with the Neurological Society of Kenya to discuss the management of brain tumors with a stimulating surgical perspective from Dr Edwin Mogere Neurosurgeon and an in-depth discussion of management of medical symptoms from brain tumors by Dr Judy Kwasa Neurologist. \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-management-of-brain-tumors/ LOCATION:Crowne Plaza Hotel CATEGORIES:CME 2019,Webinar Recording Available END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190829T200000 DTEND;TZID=Africa/Nairobi:20190829T220000 DTSTAMP:20250622T142511Z CREATED:20210420T153545Z LAST-MODIFIED:20250622T142511Z UID:4736-1567108800-1567116000@kesho-kenya.org SUMMARY:TOPIC: BCR-ABL and OSTEOGENIC SARCOMA DESCRIPTION:[vc_row][vc_column][vc_column_text]We took a well-deserved break in July 2019 and came back in August for a mixed presentation on CML and osteogenic sarcoma from Prof Nicholas Abinya Medical Oncologist and Dr Mohammed Ezzi Medical Oncologist. The outcome for patients with CML has significantly improved with TKI therapies\, yet challenges persist in adequate monitoring which is expensive. The lack of co-ordinated multidisciplinary care needed for osteogenic sarcoma led to many lost to follow up and incomplete treatments with poor outcomes. MDTs prior to treatment is a potential strategy for reversing this trend.[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-bcr-abl-and-osteogenic-sarcoma/ LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190829T170000 DTEND;TZID=Africa/Nairobi:20190829T200000 DTSTAMP:20250622T142510Z CREATED:20210420T153328Z LAST-MODIFIED:20250622T142510Z UID:4734-1567098000-1567108800@kesho-kenya.org SUMMARY:SSA Breast Cancer DESCRIPTION:[vc_row][vc_column][vc_column_text]Another busy month for us with three meetings in October. First off\, Prof Asim Jamal Medical Oncologist gave an excellent overview of presentation\, diagnosis and management of neuroendocrine tumors which are not as rare as originally felt. KESHO then partnered with Pathologists Lancet Kenya to discuss molecular diagnostics in hemato-oncology. Speakers from France and our very own experts deliberated on the changing landscape of hemato-oncology and what is practical in our setting. Finally\, a multidisciplinary webinar session on breast cancer concluded our sessions for the month in recognition of the Breast Cancer Awareness month\, with presentations from Dr. Gladwell Kiarie Medical Oncologist\, Dr. Fred Okuku Medical Oncologist\, Dr. Aba Anoa Scott Radiation/Clinical Oncologist and Prof. Ronald Wasike Breast Surgeon.[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/ssa-breast-cancer/ LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya CATEGORIES:CME 2019 END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190627T110000 DTEND;TZID=Africa/Nairobi:20190627T200000 DTSTAMP:20250622T142511Z CREATED:20210420T154157Z LAST-MODIFIED:20250622T142511Z UID:4738-1561633200-1561665600@kesho-kenya.org SUMMARY:TOPIC: Paediatric Malignancies; Optimising Care In Acute Leukaemia DESCRIPTION:[vc_row][vc_column][vc_column_text]We directed our focus on hematology and this time we concentrated on pediatric malignancies. Dr. Jamila Rajab Consultant Haematologist\, Dr. Grace Mbatia Paediatric Oncologist and Dr Festus Njuguna Paediatric Oncologist. We got a glimpse on the myriad challenges our colleagues in hematology face in the management of pediatric hematological malignancies including complicated regimens\, high rate of drop outs and poor supportive care. The outcome was to continue in the process of development of national treatment protocols that can be used which can also help in comparing treatment outcomes in the different settings.[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-paediatric-malignancies-optimising-care-in-acute-leukaemia/ LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190523T200000 DTEND;TZID=Africa/Nairobi:20190523T220000 DTSTAMP:20250622T142511Z CREATED:20210420T154450Z LAST-MODIFIED:20250622T142511Z UID:4740-1558641600-1558648800@kesho-kenya.org SUMMARY:TOPIC: Colon Cancer; A Multidisciplinary Approach DESCRIPTION:[vc_row][vc_column][vc_column_text]This was a busy month for our members with three educational events! Dr. Joe Ruturi Cardiothoracic Surgeon and Dr. Solomon Mutua Clinical Oncologist started off the month with discussions on upper GI cancers\, in particular esophageal cancer. KESHO collaborated with ROCHE in their sub-Saharan MPANGO two-day meeting in which many of our members were speakers. The conference focused on triple negative and HER2 breast cancer\, colon and lung cancer. The month ended with an excellent multidisciplinary meeting on colon cancer spearheaded by our very own past Chair\, Dr. Gladwell Kiarie Medical Oncologist and Dr. Rajendra Chauhan Surgical Oncologist. There was a lot of input from our surgical and radiation colleagues.[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-colon-cancer-a-multidisciplinary-approach/ LOCATION:Radisson Blu\, Upperhill Nairobi\, Nairobi\, Nairobi\, 00100\, Kenya CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190427T200000 DTEND;TZID=Africa/Nairobi:20190427T220000 DTSTAMP:20250622T142511Z CREATED:20210420T155152Z LAST-MODIFIED:20250622T142511Z UID:4743-1556395200-1556402400@kesho-kenya.org SUMMARY:TOPIC: HIV Malignancies Symposium DESCRIPTION:[vc_row][vc_column][vc_column_text]KESHO held a half-day joint symposium with the HIV Clinicians Society discussing the various aspects of HIV related malignancies and how we can better co-manage these patients for improved outcomes. More local research is needed to understand the true prevalence of a co-diagnosis of HIV and cancer and in particular non-AIDS defining malignancies.[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-hiv-malignancies-symposium/ LOCATION:Movenpick Hotel\, Nairobi CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190328T000000 DTEND;TZID=Africa/Nairobi:20190328T235959 DTSTAMP:20250622T142510Z CREATED:20210421T195426Z LAST-MODIFIED:20250622T142510Z UID:4784-1553731200-1553817599@kesho-kenya.org SUMMARY:Topic: Acute Leukaemia DESCRIPTION:[vc_row][vc_column][vc_column_text] \nProf. Nicholas Abinya Medical Oncologist and Dr. Anne Mwirigi Haematologist gave stimulating perspectives on their care of patients with AML in a public versus a private setting. This led to discussions on collaborations on improving standards of care in our country and in particular with regards to supportive care and financing. KESHO is now engaging with NHIF and the NCCP to outline a treatment package for these patients that factor other costs apart from direct chemotherapy drugs. \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-acute-leukaemia/ LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190228T000000 DTEND;TZID=Africa/Nairobi:20190228T235959 DTSTAMP:20250622T142510Z CREATED:20210421T200249Z LAST-MODIFIED:20250622T142510Z UID:4786-1551312000-1551398399@kesho-kenya.org SUMMARY:Topic: Updates on Recently Launched Cancer Screening Guidelines DESCRIPTION:[vc_row][vc_column][vc_column_text]In line with the launch of the Kenya Cancer Screening guidelines\, Dr Andrew Odhiambo Medical Oncologist and Dr Primus Ochieng Clinical Oncologist presented on their perspectives on the new guidelines and their experience in other settings outside of Kenya. The Screening Guidelines is as shown below: \n \n\n \n \n Loading Viewer... \n \n \n [/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-updates-on-recently-launched-cancer-screening-guidelines/ CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190131T000000 DTEND;TZID=Africa/Nairobi:20190131T235959 DTSTAMP:20250622T142510Z CREATED:20210421T200621Z LAST-MODIFIED:20250622T142510Z UID:4791-1548892800-1548979199@kesho-kenya.org SUMMARY:Topic: Updates in Breast Cancer Management DESCRIPTION:[vc_row][vc_column][vc_column_text] \nWe started off the year discussing the most common cancer in women in Kenya and worldwide with two presentations. Dr Miriam Mutebi Surgical Oncologist gave an update on the surgical techniques of breast cancer management and Dr Njoki Njiriani Clinical Oncologist talking on new therapies for advanced hormone positive breast cancer \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-updates-in-breast-cancer-management/ LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT END:VCALENDAR